Rothschild Redburn analyst Simon Baker downgraded Moderna (NASDAQ: MRNA) from Neutral to Sell with a price target of $81.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE